Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACCShell Companies
+$0.00 today
- Market cap
- $263.53M
- Beta
- -0.04
- P/E (TTM)
- 29.1
- EPS (TTM)
- $0.37
Volume 0.00M
Average 0.01M
OACC Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
Oaktree Acquisition Corp. III Life SciencesNASDAQ: OACC
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt broadly unchanged from a year ago
Short-term debt stood at $11.82K at the end of Q1 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter.
Context
- Short-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
What to watch
Whether short-term debt keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 11.82K USD
- Year-over-year change
- +0.0%
- 1-year CAGR
- +0.0%
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.82K | +0.0% |
| FY2024 | 2024-12-31 | 11.82K | — |
Short-term Debt vs competitors
How OACC compares with its peers on the latest reported figures
- OACC's Mar 2026 short-term debt of $11.82K is the 5th highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +0.0% is the 2nd highest of 6, against a peer median of -100.0%.
- Short-term debt amounts to 0.0% of total assets for OACC, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
MBAVM3-Brigade Acquisition V Corp. Class A Ordinary shares | Mar 2026 | $3.6M | — | — | 1.2% |
| Mar 2026 | $2.26M | +901.7% | — | 0.9% | |
AACBArtius II Acquisition Inc. Class A Ordinary Shares | Mar 2026 | $300K | — | — | 0.1% |
COPLCopley Acquisition Corp | Mar 2026 | $18.7K | -92.6% | — | 0.1% |
OACCOaktree Acquisition Corp. III Life Sciences | Mar 2026 | $11.82K | +0.0% | — | 0.0% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding OACC) | $0 | -100.0% | — | 0.0% | |
Competitors are the stored peer set for OACC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 1.36M | 1.43M |
| Short-term Investments | 0 | 0 |
| Net Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Other Current Assets | 0 | 0 |
| Total Current Assets | 1.56M | 1.55M |
| Property, Plant & Equipment (Net) | 0 | 0 |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-term Investments | 193.58M | 201.56M |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 113.28K | 0 |
| Total Non-current Assets | 193.69M | 201.56M |
| Total Assets | 195.25M | 203.11M |
| Account Payables | 0 | 0 |
| Short-term Debt | 11.82K | 11.82K |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 0 | 0 |
| Other Current Liabilities | 179.98K | 1.29M |
| Total Current Liabilities | 727.32K | 1.3M |
| Long-term Debt | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 |
| Other Non-current Liabilities | 7.02M | 7.02M |
| Total Non-current Liabilities | 7.02M | 7.02M |
| Total Liabilities | 7.75M | 8.32M |
| Common Stock | 193.58M | 201.56M |
| Retained Earnings | (6.08M) | (6.77M) |
| Accumulated OCI | 0 | 0 |
| Other Stockholders Equity | 0 | 0 |
| Minority Interest | 0 | 0 |
| Total Equity | 187.5M | 194.79M |
| Total Debt | 11.82K | 11.82K |
| Net Debt | (1.35M) | (1.42M) |
Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACC
Intrinsic Alpha fair value
Locked
Current Price
$10.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.